Transplantation for chronic myelogenous leukemia: Yes, no, maybe so...an Oregon perspective

Richard T. Maziarz, Michael J. Mauro

Research output: Contribution to journalShort survey

14 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disorder in which allogeneic stem cell transplantation remains the only curative option, but its use is limited by donor availability and treatment-related morbidity and mortality. Imatinib mesylate is a targeted agent for CML with efficacy to date, which is superior to all other nontransplant therapy and has limited toxicity. The curative potential of imatinib remains to be proven and may be limited to a small number of patients. Optimal decision making regarding the use of these divergent therapies has not been defined. This paper reviews critical data relevant to these treatment options and provides an approach to current management of the CML patient.

Original languageEnglish (US)
Pages (from-to)459-469
Number of pages11
JournalBone marrow transplantation
Volume32
Issue number5
DOIs
StatePublished - Sep 1 2003

    Fingerprint

Keywords

  • Allogeneic stem cell transplatation
  • Chronic myelogenous leukemia
  • Imatinib mesylate

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this